sibutramine has been researched along with Cardiovascular Diseases in 63 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 9.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 9.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 9.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS." | 9.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Combined to hypocaloric diet, sibutramine increases weight loss in obese individuals." | 9.11 | Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. ( Contaldo, F; De Caprio, C; de Simone, G; di Luzio Paparatti, U; Pasanisi, F; Romano, C; Salanitri, T, 2005) |
| "A total of 1102 obese adults (body mass index, 30-40 kg/m(2)) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period." | 9.09 | Long-term weight loss with sibutramine: a randomized controlled trial. ( Krause, J; Wirth, A, 2001) |
| "To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders." | 8.85 | The use of sibutramine in the management of obesity and related disorders: an update. ( Krassas, GE; Tziomalos, K; Tzotzas, T, 2009) |
| "Orlistat or sibutramine, when individually compared to placebo, are effective in promoting significant weight loss." | 8.84 | Orlistat and sibutramine beyond weight loss. ( Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F, 2008) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 7.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "Values for body weight, vital signs (blood pressure, heart rate), serum glucose and serum lipids remain constant even after termination of the sibutramine therapy." | 7.72 | [Sustained weight reduction after cessation of obesity treatment with Sibutramine]. ( Wirth, A, 2004) |
| "Future development of drugs for the treatment of obesity will be dependent on whether they can survive review for safety and effectiveness." | 6.47 | Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? ( Downey, M; Sharma, AM; Still, C, 2011) |
| "Obesity is a major health problem worldwide." | 5.37 | Drug treatment for obesity in the post-sibutramine era. ( Cheung, BM, 2011) |
| "The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise." | 5.19 | Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. ( Caterson, ID; Coutinho, W; Espinoza, D; Finer, N; Gebski, V; Ivers, L; James, WP; Legler, UF; Seimon, RV; Sharma, AM, 2014) |
| "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years." | 5.17 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 5.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 5.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 5.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS." | 5.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Combined to hypocaloric diet, sibutramine increases weight loss in obese individuals." | 5.11 | Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. ( Contaldo, F; De Caprio, C; de Simone, G; di Luzio Paparatti, U; Pasanisi, F; Romano, C; Salanitri, T, 2005) |
| "This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors." | 5.11 | Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. ( Gaciong, Z; Placha, G, 2005) |
| "A total of 1102 obese adults (body mass index, 30-40 kg/m(2)) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period." | 5.09 | Long-term weight loss with sibutramine: a randomized controlled trial. ( Krause, J; Wirth, A, 2001) |
| "To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders." | 4.85 | The use of sibutramine in the management of obesity and related disorders: an update. ( Krassas, GE; Tziomalos, K; Tzotzas, T, 2009) |
| "Orlistat or sibutramine, when individually compared to placebo, are effective in promoting significant weight loss." | 4.84 | Orlistat and sibutramine beyond weight loss. ( Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F, 2008) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| "Sibutramine is an anti-obesity agent that induces weight loss by selective inhibition of neuronal reuptake of serotonin and norepinephrine; however, it is associated with the risk of cardiovascular diseases (CVD), including heart attack and stroke." | 3.77 | Proteome changes in rat plasma in response to sibutramine. ( Choi, DK; Choi, JW; Joo, JI; Kim, DH; Oh, TS; Wang, X; Yun, JW, 2011) |
| "In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension." | 3.77 | [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. ( Madsbad, S, 2011) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 3.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "Values for body weight, vital signs (blood pressure, heart rate), serum glucose and serum lipids remain constant even after termination of the sibutramine therapy." | 3.72 | [Sustained weight reduction after cessation of obesity treatment with Sibutramine]. ( Wirth, A, 2004) |
| "The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized." | 3.71 | [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine]. ( Scheen, AJ, 2001) |
| " The first group received three daily 120 mg dosages of orlistat for nine months (n=39), and the second group received a once daily 10 or 15 mg dosage of sibutramine for nine months (n=37)." | 2.84 | Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects. ( Al-Safi Ismail, AA; Al-Tahami, BAM; Rasool, AHG; Sanip, Z; Shihabudin, TMT; Singh, TSP; Yusoff, Z, 2017) |
| "Future development of drugs for the treatment of obesity will be dependent on whether they can survive review for safety and effectiveness." | 2.47 | Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? ( Downey, M; Sharma, AM; Still, C, 2011) |
| "Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an antiobesity agent to reduce appetite and promote weight loss in combination with diet and exercise." | 2.46 | Cardiovascular risk-benefit profile of sibutramine. ( Scheen, AJ, 2010) |
| "Obesity is considered a worldwide epidemic." | 2.45 | Recent advances in obesity pharmacotherapy. ( Höcht, C; Mayer, MA; Puyó, A; Taira, CA, 2009) |
| "Most patients with type 2 diabetes mellitus are overweight or obese, and the relation between obesity, especially of the visceral compartment, and the risk for developing diabetes is well recognized." | 2.44 | Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. ( Aronne, LJ; Lee, M, 2007) |
| "Obesity is associated with significant increase in cardiovascular risk." | 2.43 | The obesity epidemic and its cardiovascular consequences. ( Behn, A; Ur, E, 2006) |
| "Sibutramine can produce dose-dependent increases in blood pressure and heart rate, especially during initial treatment." | 2.41 | Sibutramine and its cardiovascular profile. ( Narkiewicz, K, 2002) |
| "Obesity has now become a major target for drug development not only for affecting obesity per se but also for managing and preventing comorbid conditions such as diabetes and cardiovascular disease." | 2.40 | The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997) |
| "Obesity is a major health problem worldwide." | 1.37 | Drug treatment for obesity in the post-sibutramine era. ( Cheung, BM, 2011) |
| "Obesity is a major health problem in the United States and many other countries because of its high prevalence and causal relationship with serious medical comorbidities." | 1.35 | Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery. ( Fabbrini, E; Klein, S, 2008) |
| "Obesity is a chronic condition with complex, multiple causes involving physiologic, genetic, and behavioral components, all of which must be addressed for successful treatment." | 1.31 | Treating obesity in the family practice setting. ( Fernstrom, MH, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.59) | 18.2507 |
| 2000's | 34 (53.97) | 29.6817 |
| 2010's | 27 (42.86) | 24.3611 |
| 2020's | 1 (1.59) | 2.80 |
| Authors | Studies |
|---|---|
| Waseem, R | 1 |
| Raza, M | 1 |
| Aftab, A | 1 |
| Al-Tahami, BAM | 1 |
| Al-Safi Ismail, AA | 1 |
| Sanip, Z | 1 |
| Yusoff, Z | 1 |
| Shihabudin, TMT | 1 |
| Singh, TSP | 1 |
| Rasool, AHG | 1 |
| Winther, SA | 1 |
| Finer, N | 11 |
| Sharma, AM | 11 |
| Torp-Pedersen, C | 8 |
| Andersson, C | 3 |
| Ghotbi, AA | 1 |
| Køber, L | 2 |
| James, WP | 7 |
| Caterson, I | 2 |
| Coutinho, W | 8 |
| Van Gaal, LF | 4 |
| Seimon, RV | 2 |
| Espinoza, D | 2 |
| Ivers, L | 1 |
| Gebski, V | 2 |
| Legler, UF | 3 |
| Caterson, ID | 7 |
| Antel, J | 1 |
| Albayrak, Ö | 1 |
| Heusch, G | 1 |
| Banaschewski, T | 1 |
| Hebebrand, J | 1 |
| Van Gaal, L | 2 |
| Maggioni, AP | 5 |
| Sweeting, A | 1 |
| Gaal, LV | 1 |
| Bacher, P | 1 |
| Shepherd, G | 1 |
| Sun, R | 1 |
| James, P | 1 |
| Fabbrini, E | 1 |
| Klein, S | 1 |
| Mayer, MA | 1 |
| Höcht, C | 1 |
| Puyó, A | 1 |
| Taira, CA | 1 |
| Weeke, P | 1 |
| Fosbøl, EL | 1 |
| Brendorp, B | 1 |
| Rode, RA | 3 |
| Tziomalos, K | 1 |
| Krassas, GE | 1 |
| Tzotzas, T | 1 |
| Czernichow, S | 1 |
| Lee, CM | 1 |
| Barzi, F | 1 |
| Greenfield, JR | 1 |
| Baur, LA | 1 |
| Chalmers, J | 1 |
| Woodward, M | 1 |
| Huxley, RR | 1 |
| Fernstrom, MH | 1 |
| Ge, H | 1 |
| Moran, SA | 1 |
| Shepherd, GM | 3 |
| Phillips, CL | 1 |
| Yee, BJ | 1 |
| Trenell, MI | 1 |
| Magnussen, JS | 1 |
| Wang, D | 1 |
| Banerjee, D | 1 |
| Berend, N | 1 |
| Grunstein, RR | 1 |
| Williams, G | 1 |
| Garrow, JS | 1 |
| Harrison-Woolrych, M | 1 |
| Ashton, J | 1 |
| Herbison, P | 1 |
| Scheen, AJ | 4 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Drazen, JM | 1 |
| Renz, CL | 2 |
| Pinto, ME | 1 |
| Manrique, HA | 1 |
| Madsbad, S | 1 |
| Choi, JW | 1 |
| Joo, JI | 1 |
| Kim, DH | 1 |
| Wang, X | 1 |
| Oh, TS | 1 |
| Choi, DK | 1 |
| Yun, JW | 1 |
| Cheung, BM | 1 |
| Downey, M | 1 |
| Still, C | 1 |
| Perdok, RJ | 1 |
| Paumgartten, FJ | 1 |
| Schroeder, C | 1 |
| Jordan, J | 2 |
| Narkiewicz, K | 1 |
| Ruilope, LM | 1 |
| Garcia-Robles, R | 1 |
| Moreno, B | 1 |
| Wirth, A | 2 |
| Chaput, JP | 1 |
| Bérubé-Parent, S | 1 |
| Tremblay, A | 1 |
| de Simone, G | 2 |
| Romano, C | 1 |
| De Caprio, C | 1 |
| Contaldo, F | 1 |
| Salanitri, T | 1 |
| di Luzio Paparatti, U | 1 |
| Pasanisi, F | 1 |
| Gaciong, Z | 1 |
| Placha, G | 1 |
| Cuppini, A | 1 |
| Matteini, P | 1 |
| Wadden, TA | 1 |
| Berkowitz, RI | 1 |
| Womble, LG | 1 |
| Sarwer, DB | 1 |
| Phelan, S | 1 |
| Cato, RK | 1 |
| Hesson, LA | 1 |
| Osei, SY | 1 |
| Kaplan, R | 1 |
| Stunkard, AJ | 1 |
| Letonturier, P | 1 |
| Patel, MR | 1 |
| Donahue, M | 1 |
| Wilson, PW | 1 |
| Califf, RM | 1 |
| Behn, A | 1 |
| Ur, E | 1 |
| Pi-Sunyer, FX | 1 |
| Fujioka, K | 1 |
| Lee, M | 1 |
| Aronne, LJ | 2 |
| Dalmau Serra, J | 1 |
| Alonso Franch, M | 1 |
| Gómez López, L | 1 |
| Martínez Costa, C | 1 |
| Sierra Salinas, C | 1 |
| Lindholm, Å | 1 |
| Bixo, M | 1 |
| Björn, I | 1 |
| Wölner-Hanssen, P | 1 |
| Eliasson, M | 1 |
| Larsson, A | 1 |
| Johnson, O | 1 |
| Poromaa, IS | 1 |
| Mannucci, E | 1 |
| Dicembrini, I | 1 |
| Rotella, F | 1 |
| Rotella, CM | 1 |
| Coutinho, WF | 1 |
| Bodary, PF | 1 |
| Iglay, HB | 1 |
| Eitzman, DT | 1 |
| von Haehling, S | 1 |
| Lainscak, M | 1 |
| Anker, SD | 1 |
| D'Addeo, G | 1 |
| Weiser, M | 1 |
| Frishman, WH | 1 |
| Michaelson, MD | 1 |
| Abdeen, MA | 1 |
| Després, JP | 1 |
| Krause, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event[NCT00234832] | Phase 3 | 10,777 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults[NCT01803737] | 26 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 418 |
| Randomized Placebo | 404 |
For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 200 |
| Randomized Placebo | 159 |
For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 127 |
| Randomized Placebo | 95 |
This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 927 |
| Randomized Placebo | 856 |
For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 11 |
| Randomized Placebo | 7 |
For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 223 |
| Randomized Placebo | 229 |
For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Intent-to-treat population | |
| CV + DM Randomized to Placebo | 346 |
| CV + DM Randomized to Sibutramine | 403 |
| CV Only Randomized to Placebo | 66 |
| CV Only Randomized to Sibutramine | 77 |
| DM Only Randomized to Placebo | 77 |
| DM Only Randomized to Sibutramine | 79 |
| Randomized Placebo | 490 |
| Randomized Sibutramine | 561 |
Body weight will be measured on a digital scale to assess change in body weight over the 12-week intervention period. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kg (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -5.6 |
| Campaign Intervention (CI) | -3.1 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of carbohydrate intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.64 |
| Campaign Intervention (CI) | 0.90 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of fat intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -3.26 |
| Campaign Intervention (CI) | -0.00 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of protein intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.73 |
| Campaign Intervention (CI) | 0.44 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/day (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 474.8 |
| Campaign Intervention (CI) | 242.5 |
A questionnaire will be used to measure and quantify energy expenditure from physical activity. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/wk (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 983.3 |
| Campaign Intervention (CI) | 776.3 |
Self-efficacy for weight loss was assessed at week 0 and 12 using a 20-item Weight Efficacy Lifestyle Questionnaire (WEL). The total score ranges from 0-180. Higher values represent greater beliefs toward the completion of weight management behaviors. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 28.3 |
| Campaign Intervention (CI) | 16.3 |
The frequency that participants engaged in the self-monitoring of dietary intake and physical activity was assessed at week 12. The diaries were completed weekly throughout the study. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of diaries completed (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 91.6 |
| Campaign Intervention (CI) | 60.1 |
At week 12, participants completed the 13-item TSRQ to assess motivation to continue to participate in the program if given the opportunity. The TSRQ represents participants' reasons for continuing participation in a weight loss program via participants' endorsement of statements of autonomous and controlled motivation. Responses were given using a 7-point Likert scale (1 = not at all true to 7 = very true). The responses on the autonomous items (5) and controlled items (8) were averaged. (NCT01803737)
Timeframe: Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Autonomous Motivation | Controlled Motivation | |
| Campaign Intervention (CI) | 5.3 | 2.9 |
| Standard Behavioral Weight Loss Intervention (SBWL) | 6.3 | 2.9 |
23 reviews available for sibutramine and Cardiovascular Diseases
| Article | Year |
|---|---|
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Topics: Adolescent; Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Press | 2015 |
Recent advances in obesity pharmacotherapy.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orli | 2009 |
The use of sibutramine in the management of obesity and related disorders: an update.
Topics: Adult; Appetite Depressants; Biomarkers; Blood Glucose; Cardiovascular Diseases; Child; Cyclobutanes | 2009 |
Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Lipids; Ob | 2010 |
Cardiovascular risk-benefit profile of sibutramine.
Topics: Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cyclobutanes; Gluco | 2010 |
Sibutramine on cardiovascular outcome.
Topics: Appetite Depressants; Cardiovascular Diseases; Cardiovascular System; Cyclobutanes; Humans | 2011 |
Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?
Topics: Advisory Committees; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Cyclobu | 2011 |
Norepinephrine transporter function and human cardiovascular disease.
Topics: Appetite Depressants; Autonomic Nervous System; Cardiovascular Diseases; Cardiovascular System; Cycl | 2012 |
Sibutramine and its cardiovascular profile.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Hemodynamics; Humans | 2002 |
Obesity, cardiovascular risk and pharmacotherapy.
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; | 2002 |
Obesity and cardiovascular physiology: impact of some pharmacological agents.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cardiovascular Physiolo | 2005 |
[Obesity and metabolic syndrome: clinical and therapeutic review].
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Diseases; Cyclobutanes; Exercise; | 2005 |
Clinical trial issues in weight-loss therapy.
Topics: Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidit | 2006 |
The obesity epidemic and its cardiovascular consequences.
Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; | 2006 |
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Pip | 2006 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
Metabolic syndrome treatment strategies.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; O | 2006 |
Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cyclobutanes; Diabet | 2007 |
Therapeutic options for modifying cardiometabolic risk factors.
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hypoglycem | 2007 |
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy | 2007 |
Orlistat and sibutramine beyond weight loss.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hyp | 2008 |
Strategies to reduce vascular risk associated with obesity.
Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; | 2007 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo | 1997 |
16 trials available for sibutramine and Cardiovascular Diseases
| Article | Year |
|---|---|
Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
Topics: Adiponectin; Adolescent; Adult; Aged; Asian People; Blood Glucose; Body Fat Distribution; Body Mass | 2017 |
Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients.
Topics: Anemia; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Blind Me | 2014 |
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female; | 2013 |
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet | 2014 |
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabetic Angiopa | 2015 |
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet | 2008 |
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Topics: Aged; Appetite Depressants; Bilirubin; Biomarkers; Cardiovascular Diseases; Confounding Factors, Epi | 2009 |
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind | 2012 |
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobu | 2005 |
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobutanes; Dia | 2005 |
Randomized trial of lifestyle modification and pharmacotherapy for obesity.
Topics: Adult; Appetite Depressants; Cardiovascular Diseases; Combined Modality Therapy; Counseling; Cyclobu | 2005 |
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Appetite Depressants; Body Weight; Cardiovascular Diseases; Cyclobutanes; Double- | 2008 |
The obese older female patient: CV risk and the SCOUT study.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Exercise; | 2007 |
Long-term weight loss with sibutramine: a randomized controlled trial.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Bli | 2001 |
24 other studies available for sibutramine and Cardiovascular Diseases
| Article | Year |
|---|---|
Accentuating cardiovascular events in Sibutramine-treated patients.
Topics: Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Humans; Weight Loss | 2021 |
Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cy | 2008 |
Treating obesity in the family practice setting.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; H | 2001 |
Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Appetite Depressants; Biomarkers; Cardiovascular Diseases; C | 2009 |
Withdrawal of sibutramine in Europe.
Topics: Aged; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Europe; Humans; Middle Aged; Obes | 2010 |
Withdrawal of sibutramine. Editorial is judgment in advance of the facts.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Cyclobutanes; Humans; Obesit | 2010 |
Withdrawal of sibutramine. Magic bullets now uncontrolled.
Topics: Advertising; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Fraud; Humans; Obesity; Saf | 2010 |
Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Appetite Depressants; Cardiovascular Diseases; | 2010 |
Controversy about the cardiovascular safety of sibutramine.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Obesity; Risk | 2010 |
Sibutramine: cardiovascular events.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans | 2010 |
Sibutramine--another flawed diet pill.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Myocardial Infarction; Obesity; | 2010 |
Sibutramine (Meridia) withdrawn.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Safety-Based Drug Withdrawals | 2010 |
[Withdrawal of sibutramine for cardiovascular disease risk].
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Risk Factors | 2010 |
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobuta | 2011 |
Proteome changes in rat plasma in response to sibutramine.
Topics: Adipose Tissue; Animals; Appetite Depressants; Appetite Regulation; Blood Proteins; Body Weight; Car | 2011 |
Drug treatment for obesity in the post-sibutramine era.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Child; Cy | 2011 |
Long-term health benefits of appetite suppressants remain unproven.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Clinical Trials as Topic; | 2011 |
Potential for sibutramine-yohimbine interaction?
Topics: Animals; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyclobutanes; Drug Interactions; Humans; H | 2003 |
[Sustained weight reduction after cessation of obesity treatment with Sibutramine].
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobuta | 2004 |
[Reducing obesity].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Child; Cyclobutan | 2006 |
Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Humans; Obesity; R | 2007 |
Sibutramine: balancing weight loss benefit and possible cardiovascular risk.
Topics: Antidepressive Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Eating; Evidence | 2008 |
[Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Europe; Humans; Mu | 2001 |
Drug treatment for obesity. We need more studies in men at higher risk of coronary events.
Topics: Adult; Appetite Depressants; Cardiovascular Diseases; Cholesterol, LDL; Cyclobutanes; Female; Humans | 2001 |